November, 2012 -- Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka,
Japan; hereinafter “Interprotein”) today announced the result of assessment of
small molecule PPI inhibitors that were designed by INTENDD (Interprotein’s
Engine for New Drug Design), a platform technology of Interprotein, under the
collaborative research between Takeda Pharmaceutical Company Limited
(Headquarters: Osaka, Japan; hereinafter “Takeda”) and Interprotein.
The compounds designed by Interprotein were assessed at Takeda for binding to
the target protein at the molecular level, and approximately 11%*)
compounds tested were confirmed to bind to the target protein. Takeda will
proceed with further evaluation of the compounds based on the results.
*) It is generally recognized that hit rates of compounds against protein targets through
computational drug design methods are well below 11%.
Hirotsugu KOMATSU, Ph.D.